In Re Showa Denko

953 F.2d 162, 1992 U.S. App. LEXIS 251
CourtCourt of Appeals for the Fourth Circuit
DecidedJanuary 10, 1992
Docket91-8074
StatusPublished
Cited by19 cases

This text of 953 F.2d 162 (In Re Showa Denko) is published on Counsel Stack Legal Research, covering Court of Appeals for the Fourth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In Re Showa Denko, 953 F.2d 162, 1992 U.S. App. LEXIS 251 (4th Cir. 1992).

Opinion

953 F.2d 162

In re SHOWA DENKO K.K. L-TRYPTOPHAN PRODUCTS LIABILITY
LITIGATION-II.
Lola J. RAPOPORT and Leonard Rapoport, Respondents,
v.
SHOWA DENKO K.K.; Showa Denko of America, Incorporated, Petitioners,
and
Solgar Company, Incorporated; General Nutrition
Corporation; Twin Laboratories, Incorporated; Walgreen
Company; Walgreen Laboratories, Incorporated; Triarco
Corporation; P. Leiner Nutritional Products, Incorporated;
Revco Drug Stores, Incorporated; Merchandisers,
Incorporated; Xcel Laboratories, Incorporated; Ajinomoto
USA, Incorporated; Mitsuitoatsu Chemicals, Incorporated;
MTC America, Incorporated; American Drug Stores,
Incorporated; Bergen Brunswig Drug Company; Safeway,
Incorporated; Nature Made Nutritional Products; Ide
Interstate; Goldline Laboratories, Incorporated; Nutro
Laboratories, Incorporated; Leroy Pharmacies, Incorporated;
Natures Bounty, Incorporated; Vitamin Shoppe,
Incorporated; Natrol Incorporated; Jameson Pharmaceutical
Corporation; Bio-Energy, Incorporated; Now Foods,
Incorporated; Puritan's Pride, Incorporated; Natural
Wealth, Incorporated; Albertson's Incorporated; Source
Naturals, Incorporated; Vitamin Power, Incorporated;
Health Food Shoppe of Fort Wayne; Osco Drugs, Incorporated;
Contract Pharmacal Corporation; Star Professional
Pharmaceuticals, Incorporated, dba Star Pharmaceuticals,
Incorporated; Goldline, Incorporated; Amcon Industries,
Incorporated; Interstate Drug Exchange, Incorporated;
Life-Line Nutritional Products, Incorporated; Nutrilite
Products, Incorporated; Wal-Mart Stores, Incorporated;
Jameson Nutritional Division; Rugby Laboratories,
Incorporated; Rugby-Darby Group Companies, Incorporated;
Rugby-Darby Group, Incorporated; Nutrition Headquarters,
Incorporated; Bio-Organic Brands, Incorporated; Eastern
Vitamins; Freshlabs, Incorporated; Makers of Kal,
Incorporated; Natural Alternatives International,
Incorporated; Orlove Enterprises, Incorporated; Stur-Dee
Health Products, Incorporated; Windmill Natural Vitamin
Company; Garden State Nutritionals, Incorporated; Nature
Products, Incorporated; Pharnavite Corporation, Defendants.

No. 91-8074.

United States Court of Appeals,
Fourth Circuit.

Argued Dec. 5, 1991.
Decided Jan. 10, 1992.

Edwin B. Mishkin, Cleary, Gottlieb, Steen & Hamilton, New York City, argued (George J. Grumbach, Jr., Edmund H. Kerr, Richard W. Hulbert, Daniel J.H. Greenwood, Norman Menachem Feder, Michael R. Chayet, Cleary, Gottlieb, Steen & Hamilton, New York City, Donald L. Morgan, Richard deC. Hinds, Washington, D.C., on brief), for petitioners.

Roger Paul Brosnahan, Robins, Kaplan, Miller & Ciresi, Minneapolis, Minn., argued (Jerry W. Blackwell, Robins, Kaplan, Miller & Ciresi, Minneapolis, Minn., Thomas Dewitt Rogers, III, Ness, Motley, Loadholt, Richardson & Poole, Charleston, S.C., William S. Davies, Jr., Nelson, Mullins, Riley & Scarborough, Columbia, S.C., on brief), for respondents.

Before MURNAGHAN, WILKINSON and NIEMEYER, Circuit Judges.

NIEMEYER, Circuit Judge:

We are asked to review an administrative order, Order No. 7, entered in the L-Tryptophan multi-district litigation, MDL Docket No. 865, pending in the District of South Carolina, where over 470 federal cases have been consolidated for pretrial proceedings. Showa Denko K.K. and Showa Denko America, Inc. (collectively Showa Denko), together with some 300 other defendants, are sued for damages for personal injury resulting from the ingestion of pills containing the amino acid L-Tryptophan.

The district court entered Order No. 7 to provide a funding mechanism to reimburse members of a steering committee of plaintiffs' lawyers, principally for discovery-generated expenses incurred on behalf of the plaintiffs. The intent of the order is to require each plaintiff in the United States who has a claim based on injury from L-Tryptophan to pay $1,000 into a common fund, plus 0.5% of any settlement reached or verdict entered (with a credit for the initial $1,000 assessment), on the theory that, whether a plaintiff settles or litigates, he or she benefits from the discovery. Consequently, the order attempts to reach not only plaintiffs in cases pending in the multi-district litigation, but also plaintiffs in federal cases not transferred to the multidistrict litigation, plaintiffs in some 683 pending state cases, and approximately 180 claimants known to Showa Denko who have not yet filed suit in any court. The district court's order seeks to enforce the assessments by requiring Showa Denko to "certify" that the assessments have been paid by plaintiffs and claimants whenever it settles or pays a verdict in a case or discloses discovery materials generated in the multi-district litigation. The order provides, in pertinent part:

2. In all cases presently filed or later filed in these proceedings, plaintiff's counsel shall initially deposit One Thousand Dollars ($1,000.00) for each injured plaintiff (excluding consortium claims) into Plaintiffs' Expense Fund....

3. At the close of any of these cases by settlement, verdict or otherwise, plaintiff's counsel shall deposit into Plaintiffs' Expense Fund one-half of one percent (0.5%) of the total sum, including consortium claims, for discovery and other approved expenses. A credit shall be applied for prior assessments paid....

4. The assessments contained in paragraphs 2 and 3 above shall also apply to actions venued in state courts, untransferred federal cases, and unfiled claims in which any MDL defendant is a party or payor.

5. At the close of any case by settlement, verdict, or otherwise, defendants [Showa Denko] shall certify that payments in amounts described in paragraphs 2, 3, and 4 above have been made ... provided that upon notice and cause shown by the plaintiff or defendants in non-MDL cases the court may order such payments to be reduced or waived. No party shall furnish to any non-MDL plaintiff any product of the MDL discovery or permit its use until ascertaining that such plaintiff has complied with this court's confidentiality orders and is current in payments of the assessments herein.

The court concluded its order with the certification required for immediate appeal pursuant to 28 U.S.C. § 1292(b).

Showa Denko appeals, alleging jurisdiction in this court under 28 U.S.C. §§ 1291 and 1292(a) (1988), and petitions for permission to appeal under 28 U.S.C. § 1292(b). On the merits, Showa Denko does not contest the district court's authority to establish the plaintiffs' expense fund and to require fixed contributions by plaintiffs in actions before the court. It does, however, contend that paragraphs 3, 4 and 5 of the order exceed the district court's authority because they (1) will impair Showa Denko's ability to settle cases with state court plaintiffs; (2) may prevent Showa Denko from providing state court plaintiffs' discovery in state proceedings; (3) may prevent Showa Denko from complying with state court orders; (4) will conflict with judgments rendered against Showa Denko in state courts; and (5) will interfere with Showa Denko's ability to keep settlements confidential.

The plaintiffs' steering committee contests our jurisdiction, principally on the ground that Order No.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Ashton v. Al Qaeda Islamic
S.D. New York, 2019
Slamon v. Carrizo (Marcellus) LLC
M.D. Pennsylvania, 2019
In re Cook Med., Inc.
365 F. Supp. 3d 685 (U.S. District Court, 2019)
Riceland Foods, Inc. v. Bayer CropScience US
835 F.3d 822 (Eighth Circuit, 2016)
Kowalchik v. Brohl
2012 COA 25 (Colorado Court of Appeals, 2012)
Adams v. Corrections Corp. of America
264 P.3d 640 (Colorado Court of Appeals, 2011)
Lee v. Thompson
43 So. 3d 1104 (Mississippi Supreme Court, 2010)
Herbert Lee, Jr. v. Gloria Thompson
Mississippi Supreme Court, 2008
In Re Zyprexa Products Liability Litigation
467 F. Supp. 2d 256 (E.D. New York, 2006)
Delaventura v. Columbia Acorn Trust
417 F. Supp. 2d 147 (D. Massachusetts, 2006)
In Re Silica Products Liability Litigation
398 F. Supp. 2d 563 (S.D. Texas, 2005)
In re Linerboard Antitrust Litigation
223 F.R.D. 357 (E.D. Pennsylvania, 2004)
Royster v. Food Lion Inc
Fourth Circuit, 1998
Abbent v. Eastman Kodak Co.
938 F. Supp. 266 (D. New Jersey, 1996)

Cite This Page — Counsel Stack

Bluebook (online)
953 F.2d 162, 1992 U.S. App. LEXIS 251, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-showa-denko-ca4-1992.